Is Eli Lilly a Millionaire Maker?
Eli Lilly’s GLP-1 drug portfolio should power the business for at least the next decade. But the market…
Massive sales for weight loss drugs spur Eli Lilly’s Q3
As weight loss market rival Novo Nordisk drew headlines for starting a bidding war over a potential $9bn…
Eli Lilly says weight-loss pill a candidate for speedy approval under new US program
By Mrinalika Roy and Patrick Wingrove (Reuters) -Eli Lilly said on Thursday its experimental weight-loss pill met most…
Lilly invests in epigenetic reprogramming biotech
NewLimit adds $45m in new funding at a $1.6bn valuation following preclinical progress that brings clinical trials closer…
Trump’s $150 Ozempic? Oz cautions it’s not a done deal, but patients and doctors say it could be a gamechanger
Janet McCaskill was on vacation in Arizona with her husband and best friend when she heard that President…
Trump’s $150 Ozempic? Oz cautions it’s not a done deal, but patients and doctors say it could be a gamechanger
Janet McCaskill was on vacation in Arizona with her husband and best friend when she heard that President…
LLY’s Oral GLP-1 Pill Scores Another Pair of Diabetes Wins
Eli Lilly LLY announced positive top-line data from two late-stage studies evaluating orforglipron, its once-daily oral GLP-1 pill, in…
Warning after ‘King Kong’ of weight-loss jabs found being sold illegally on social media
Fake versions of highly sought-after weight-loss jabs are being sold illegally on social media, an investigation has found.…
1 Reason Eli Lilly (LLY) Is One of the Best Healthcare Stocks You Can Buy Today
Eli Lilly (NYSE: LLY) has been one of the best-performing healthcare giants over the past decade. It now…
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly
By Bhanvi Satija and Maggie Fick LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and…
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly
By Bhanvi Satija and Maggie Fick LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and…
These 2 AI Stocks Could Surpass Oracle in Market Cap by 2030
Although it is a major AI infrastructure operator, Oracle’s excessive reliance on a few mega-deals and its high…